Your browser doesn't support javascript.
loading
Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.
Zhu, Lucheng; Zou, Changlin; Zhang, Zhanchun; Wang, Jianfang; Yang, Li; Rao, Chuangzhou; Yang, Zhiping; Liang, Jiafeng; Xia, Bing; Shenglin, M A.
Afiliação
  • Zhu L; Department of Thoracic Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, 310002, People's Republic of China.
  • Zou C; Department of Radiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325100, People's Republic of China.
  • Zhang Z; Department of Radiotherapy, Ningbo Medical Center Lihuili Hospital, Ningbo, 315100, People's Republic of China.
  • Wang J; Department of Radiotherapy, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, 312000, People's Republic of China.
  • Yang L; Department of Pulmonary & Critical Care Medicine, Shulan (Hangzhou) Hospital, Affiliated to Zhejiang Shuren University Shulan International Medical college, Hangzhou, 310022, People's Republic of China.
  • Rao C; Department of Radiotherapy & Chemotherapy,Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, 315010, People's Republic of China.
  • Yang Z; Department of Oncology, Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing, 314000, People's Republic of China.
  • Liang J; Department of Thoracic Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, 310002, People's Republic of China.
  • Xia B; Department of Thoracic Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, 310002, People's Republic of China. bingxia_hzch@163.com.
  • Shenglin MA; Department of Oncology, Jiande Second People's Hospital, Hangzhou, 311604, People's Republic of China. bingxia_hzch@163.com.
BMC Cancer ; 21(1): 511, 2021 May 07.
Article em En | MEDLINE | ID: mdl-33962566
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Inibidores de Proteínas Quinases / Quimiorradioterapia / Indóis / Neoplasias Pulmonares / Mutação Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Inibidores de Proteínas Quinases / Quimiorradioterapia / Indóis / Neoplasias Pulmonares / Mutação Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article